Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on ORIC-114 PK in Healthy Subjects
NCT06012721Phase 1Completed
- Sponsor
- ORIC Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enozertinib in non-small cell lung cancer (NSCLC) and solid tumor (advanced stage) (4 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 14 days, Time of Maximum Observed Concentration at 14 days and 2 more. Started Sep 2023; status: completed.
02
Drugs
enozertinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06012721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012721.